Neuroblastoma Panel
Use
The Neuroblastoma Panel is designed for individuals with a clinical or suspected diagnosis of neuroblastoma. It is also suitable for individuals with a family history of neuroblastoma, ganglioneuroma, or ganglioneuroblastoma in two or more first-degree relatives, as well as those with bilateral neuroblastoma. The test aids in the diagnosis and genetic profiling of neuroblastoma to guide patient management and familial risk assessment.
Special Instructions
Tests are available for both blood and tissue specimens. For institutional clients, standard pricing is available upon signing in. Options for STAT testing are provided at an additional surcharge, which ensures faster results turnaround, though this surcharge will not apply if the report is delivered after 16 days for submissions on blood samples.
Limitations
The test, developed by PreventionGenetics, follows CAP and CLIA guidelines but is not cleared or approved by the FDA. The accuracy might be limited by the coverage of the 15 genes included in this panel, which might not encompass all genetic variations associated with neuroblastoma. Additionally, detection of copy number variations (CNVs) might have limitations due to the resolution of the PGselect platform.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
7-16 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided